SecBot SecBot
8-K ·Filed Nov 9, 2026

TRVI

Trevi Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 10h ago SEC0001193125-26-453670
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor the Phase 2b LAKE trial SSRE analysis expected early Q1 2027 and the initiation of the non-IPF ILD Phase 2 trial in Q1 2027. Topline data from the Phase 3 OCEAN-2 trial is expected in H2 2027, a key catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

Haduvio

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
If Phase 3 trials succeed, a New Drug Application submission could occur in 2028-2029, with potential FDA approval and launch in 2029-2030 for the IPF chronic cough indication, assuming standard review timelines.
Next catalyst
None dated

What to watchThe next major catalyst is topline data from the Phase 3 OCEAN-1 trial in IPF-related chronic cough, expected in 2027. Positive data would validate the Phase 2b signal and likely drive the stock toward the $28 mean analyst target; negative data would be a severe blow given Haduvio is Trevi's only pipeline asset. A Phase 2 start in non-IPF ILD chronic cough is planned for Q1 2027, and the cash runway into 2030 eliminates near-term financing risk.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$14.91
T+0 close · Nov 9, 2026 · via day close
Latest settled
−0.64%
T+1 · $14.82 · next T+5 in 4h
Vs SPY
−1.96%
α at T+1
Latest observation
−7.11%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $14.91entry
  2. T+1 · 6d ago −0.64%α −1.96% · $14.82
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Trevi Therapeutics reported a Q3 2026 net loss of $21.5 million, wider than the $11.8 million loss in Q3 2025, driven by increased R&D spending on Phase 3 OCEAN trials. The company highlighted FDA alignment on the non-IPF ILD program, initiation of the Phase 3 OCEAN-2 trial, and a USPTO Notice of Allowance extending patent protection to 2041. Cash runway into 2030 supports key milestones.

Key Financial Metrics

EPS
−$0.13

Key Facts

  • Q3 2026 net loss of $21.5 million vs $11.8 million in Q3 2025
  • Cash, cash equivalents and marketable securities of $299.4 million at September 30, 2026
  • Phase 3 OCEAN-2 trial initiated in Q3 2026; both OCEAN trials actively recruiting
  • Positive FDA meeting on non-IPF ILD program; Phase 2 dose-ranging trial expected Q1 2027
  • USPTO Notice of Allowance for patent covering nalbuphine ER dosing in hepatically impaired patients with non-IPF ILD-related chronic cough, expiring 2041
  • Phase 2b LAKE trial in RCC progressing; SSRE analysis expected early Q1 2027
  • R&D expenses increased to $19.1 million from $10.1 million year-over-year
  • Cash runway expected into 2030

Financial Impact

Net loss widened by $9.7 million year-over-year; cash position increased to $299.4 million from $171.8 million at Q1 2026 end, reflecting the ~$162M April 2026 offering

net losscash positionR&D expenses

Risk Factors

  • Clinical trial enrollment and data readout risks across three programs
  • Net loss widening as R&D spending increases with multiple active trials
  • No FDA-approved therapies in target indications; regulatory path remains uncertain

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-453670
Document: trvi-20261109.htm0001193125-26-453670
Document: 0001193125-26-453670-index-headers.html0001193125-26-453670
Document: 0001193125-26-453670-index.html0001193125-26-453670
Document: 0001193125-26-453670.txt0001193125-26-453670
8-K Data (Synthetic)0001193125-26-453670

Track record

12 reports on TRVI

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +15.38% at T+60 after the Mar 9, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 4/10 Viewing Entry $14.91 Now $13.29 −10.87% settles Dec 9
  2. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 Now $13.29 −1.70% settles Nov 25
  3. Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
  4. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
  5. Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 Now $13.29 −10.20% ▼ −10.54% −13.71% vs SPY
  6. Apr 20, 202630w ago Press Release Neutral 5/10 Entry $14.62 to $13.43 Now $13.29 −9.10% ▼ −8.14% −13.05% vs SPY
  7. Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 Now $13.29 +13.70% ▲ +12.79% +16.99% vs SPY
  8. Apr 17, 202630w ago 8-K Bearish 7/10 Entry $15.23 to $15.08 Now $13.29 +12.74% ▲ +0.98% +6.36% vs SPY
  9. Apr 16, 202630w ago Press Release Neutral 6/10 Entry $15.23 to $15.08 Now $13.29 −12.74% ▼ −0.98% −6.36% vs SPY
  10. Mar 17, 202634w ago Press Release Mixed 6/10 Entry $10.69 to $14.54 Now $13.29 +24.32% ▲ +36.02% +29.97% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026